# ZS Ph2/3 Dose-response Study in Japan

> **NCT03127644** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 103 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** Sodium Zirconium Cyclosilicate (ZS) 5g
- **DRUG:** Sodium Zirconium Cyclosilicate (ZS) 10g
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03127644
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2018-02-23
- **Final completion:** 2018-02-23
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127644, "ZS Ph2/3 Dose-response Study in Japan". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03127644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*